Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 597 of 6351
-
New pill AVZO-023 takes on advanced breast cancer in first human trial
Disease control Recruiting nowThis study, the first clinical trial of AVZO-023, aims to determine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-023 in patients with advanced solid tumors. AVZO-023 is an oral medication that inhibits c…
Phase 1/2 • Sponsor: Avenzo Therapeutics, Inc. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
HIV breakthrough? drug may let patients ditch daily meds
Disease control By invitation onlyEven though HIV medicine stops the virus from making more copies of itself, the virus remains in the body by hiding inside of immune cells. This hidden virus is referred to as the "latent reservoir." Researchers on this team are studying whether stimulating the immune system can …
Phase 2 • Sponsor: Michael Peluso, MD • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Could a few radiation sessions be enough for breast cancer?
Disease control Recruiting nowTo learn about the effects of shorter RNI regimens in patients with breast cance who have had a lumpectomy or mastectomy and who are at higher risk for lower risk for the disease returning.
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New radiation drug targets Hard-to-Treat cancers
Disease control Recruiting nowBackground: Some cancers have high levels of proteins called somatostatin receptors (SSTRs) on the surface of the tumors. These tumors can be in the lung, head and neck, digestive tract, kidneys, and in or near the adrenal glands. Researchers want to know if drug treatments that…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Chemotherapy directly into the belly: a new hope for advanced stomach cancer?
Disease control Recruiting nowThis study is being done to answer the following questions: Can we lower the chance of your gastric cancer from growing or spreading by administering paclitaxel chemotherapy directly into your abdominal cavity in addition to chemotherapy given through a vein in your arm? Will ad…
Phase 2/3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New cocktail aims to outsmart resistant prostate cancer
Disease control Recruiting nowThis research is being done to determine if receiving the combination of testosterone and ZEN-3694 followed by the combination of enzalutamide plus ZEN-3694 will decrease the size of tumors in patients with prostate cancer that has become resistant to castration and other therapi…
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy targets hard-to-treat lymphoma
Disease control Recruiting nowThis study will treat patients with diffuse large B-cell lymphoma (DLBCL). It will assess the anti-tumor efficacy and safety of DZD8586 combination therapy by using objective response rate and the incidence and severity of adverse events. It will also measure the levels of DZD858…
Phase 1/2 • Sponsor: Dizal Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New shot could simplify prostate cancer treatment
Disease control Recruiting nowHormone therapy, or androgen deprivation therapy (ADT) is a standard way to treat prostate cancer. It works by reducing the amount of the main male sex hormone, testosterone in the body. Androgen receptor pathway inhibitors (ARPIs) are another type of hormone therapy. They either…
Phase 2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New trial tests CPAP combo to save lives in breathing crisis
Disease control Recruiting nowDe novo hypoxemic acute respiratory failure (hARF) is one of the main causes of intensive care unit (ICU) admission. In de novo hARF, intubation is associated with a dramatic increase in mortality rate. Compared to standard oxygen, the use of high-flow oxygen nasal cannula (HFNC)…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Engineered immune cells take aim at stubborn leukemia after transplant
Disease control Recruiting nowTo observe the efficacy and safety of CD7-targeted chimeric antigen receptor T cells in the treatment of T-lymphoblastic leukaemia/lymphoma with postive measurable residual disease positive post allogeneic stem cell transplantation
Phase 1 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New drug combo aims to stall advanced breast cancer
Disease control Recruiting nowThis multicenter, prospective phase II clinical trial evaluates the efficacy and safety of sequential Trastuzumab rezetecan followed by dalpiciclib plus endocrine therapy (fulvestrant or aromatase inhibitors) in 45 patients with HR+/HER2-low/ultra-low advanced breast cancer. Enro…
Phase 2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New CAR T-Cell therapy takes on rare blood disease
Disease control Recruiting nowOpen-label Phase 1b/2 study with primary objective of this study is to evaluate the safety, tolerability and efficacy of AZD0120 in participants with light chain (AL) amyloidosis.
Phase 1/2 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Gene therapy trial targets Parkinson's at its genetic root
Disease control CancelledThe goal of this clinical trial is to learn about the safety of CAP-003 gene therapy in adults with GBA1 associated Parkinson's Disease. It will also provide information about whether CAP-003 demonstrates efficacy in these adults. Participants will have a single intravenous infu…
Phase 1/2 • Sponsor: Capsida Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug combo shows promise in tough pancreatic cancer
Disease control OngoingThis study is testing narmafotinib, a type of drug called a focal adhesion kinase (FAK) inhibitor, when it is given in combination with 4 chemotherapy drugs in a regimen called FOLFIRINOX, to patients who have pancreatic cancer which has metastasised (spread). The study is being …
Phase 1/2 • Sponsor: Amplia Therapeutics Limited • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug rilzabrutinib aims to tame rare blood disorder
Disease control Recruiting nowThis is a parallel-group, Phase 3, double-blind, 2-arm study to investigate the efficacy, safety, PK and PD of oral rilzabrutinib in achieving durable Hb response (DHR) compared with placebo in approximately 90 male and female participants ≥ 18 years of age with a confirmed diagn…
Phase 3 • Sponsor: Sanofi • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New scan could spot prostate cancer more accurately
Diagnosis Recruiting nowThis is an open label, longitudinal Phase 3 study of prostate specific membrane antigen (PSMA) positron emission tomography (PET) combined with magnetic resonance imaging (MRI) compared to standard of care (SOC) for the detection of prostate cancer (PCa).
Phase 3 • Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited • Aim: Diagnosis
Last updated Jul 25, 2026 00:00 UTC
-
New hope for lung cancer patients with stubborn mutation
Disease control Recruiting nowThis is a Phase II, Open Label, Multicenter, Single Arm Study of WSD0922-FU for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with First-Line Osimertinib Treatment and whose Tumors harbor a C797S mutation within the Epidermal…
Phase 2 • Sponsor: Wayshine Biopharm, Inc. • Aim: Disease control
Last updated Jun 26, 2026 14:42 UTC
-
New drug tarlatamab targets Hard-to-Treat brain tumors
Disease control Recruiting nowThis is a phase 2 study to assess how useful study drug tarlatamab is for the treatment of patients with recurrent/refractory oligodendroglioma or astrocytoma with a mutation in the IDH gene.
Phase 2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 26, 2026 19:02 UTC
-
New pill aims to keep depression away longer
Disease control Recruiting nowThe primary objective of this study is to evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in delaying relapse of depressive symptoms (maintenance of effect) in participants with MDD.
Phase 3 • Sponsor: Neurocrine Biosciences • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New hope for stomach cancer: experimental combo enters final trial phase
Disease control Recruiting nowThis study aims to evaluate the efficacy and safety of SHR-A1811 combined with chemotherapy and immune checkpoint inhibitor versus standard first-line therapy in gastric or gastroesophageal junction adenocarcinoma.
Phase 3 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC